retatrutide phase 2 trial obesity triple agonist for diabetes type hormone receptor metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide is gaining attention in – Lilly's triple agonist, retatrutide, delivered
Pay in 4 interest-free payments of $6.40 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

























